Key Points
- Director Keith Meister sold 95,000 Illumina shares at an average price of $203.29, generating approximately $19.3 million. He retained 1,994,425 shares after the transaction, representing a 4.55% reduction in his ownership.
- Illumina reported quarterly earnings of $1.31 per share and revenue of $1.16 billion, exceeding analyst estimates; revenue rose 9.4% year over year. Fiscal 2026 EPS guidance remains $5.30–$5.40.
- Analyst sentiment is mixed: several firms raised their price targets, but the overall consensus rating remains Hold with an average target of $188.40, below the stock’s recent trading level. Institutional investors own approximately 89.4% of the company.
Illumina, Inc. (NASDAQ:ILMN - Get Free Report) Director Keith Meister sold 95,000 shares of the company's stock in a transaction dated Wednesday, August 19th. The shares were sold at an average price of $203.29, for a total value of $19,312,550.00. Following the completion of the sale, the director directly owned 1,994,425 shares of the company's stock, valued at approximately $405,446,658.25. This trade represents a 4.55% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink.
Illumina Stock Up 2.9%
ILMN stock opened at $219.40 on Friday. The company has a fifty day moving average price of $188.01 and a 200 day moving average price of $152.44. Illumina, Inc. has a 12 month low of $88.00 and a 12 month high of $220.43. The company has a debt-to-equity ratio of 0.53, a current ratio of 1.80 and a quick ratio of 1.40. The company has a market cap of $33.13 billion, a price-to-earnings ratio of 40.93, a price-to-earnings-growth ratio of 3.00 and a beta of 1.45.
Illumina (NASDAQ:ILMN - Get Free Report) last posted its quarterly earnings data on Thursday, July 30th. The life sciences company reported $1.31 EPS for the quarter, beating the consensus estimate of $1.23 by $0.08. Illumina had a return on equity of 29.84% and a net margin of 18.36%.The firm had revenue of $1.16 billion during the quarter, compared to the consensus estimate of $1.13 billion. During the same period in the prior year, the business earned $1.19 EPS. The firm's revenue was up 9.4% compared to the same quarter last year. Illumina has set its FY 2026 guidance at 5.300-5.400 EPS. Sell-side analysts expect that Illumina, Inc. will post 5.36 earnings per share for the current year.
Trending Headlines about Illumina
Here are the key news stories impacting Illumina this week:
- Positive Sentiment: Illumina’s latest quarterly results exceeded expectations, with earnings of $1.31 per share versus the $1.23 consensus estimate and revenue of $1.16 billion versus expectations of $1.13 billion. Revenue increased 9.4% year over year, while fiscal 2026 EPS guidance remains $5.30-$5.40. Illumina stock information
- Positive Sentiment: Several institutional investors increased their positions, including Marshall Wace, Cresset Asset Management and Empowered Funds. Hedge funds and other institutions collectively own approximately 89.4% of ILMN shares, indicating strong professional-investor participation.
- Neutral Sentiment: Analyst opinions remain mixed. Zacks Research upgraded the stock to “strong buy,” and Leerink Partners raised its target to $210, while Deutsche Bank downgraded the shares to “hold.” The overall consensus rating is “hold,” with an average target of $188.40—below recent trading levels. Analyst coverage of Illumina
- Negative Sentiment: Director Keith A. Meister sold 679,574 Illumina shares from August 19 through August 21 for approximately $145.6 million. The transactions reduced his ownership by roughly one-third, although he still holds about 1.41 million shares. The size and timing of the sales may raise concerns about insider conviction, even though the filings do not establish the reason for the transactions. SEC insider ownership filing
- Negative Sentiment: SVP Christensen Jakob Wedel also sold 1,033 shares under a pre-arranged Rule 10b5-1 trading plan. The smaller, planned transaction is less concerning than Meister’s sales but adds to the recent pattern of insider selling. Illumina insider trading alert
Analysts Set New Price Targets
A number of equities research analysts recently commented on the stock. Weiss Ratings upgraded shares of Illumina from a "hold (c-)" rating to a "hold (c)" rating in a research report on Wednesday, June 3rd. Wall Street Zen upgraded Illumina from a "hold" rating to a "buy" rating in a research report on Saturday, August 1st. Stifel Nicolaus increased their target price on Illumina from $155.00 to $225.00 and gave the stock a "buy" rating in a research note on Friday, July 31st. Leerink Partners raised their price target on Illumina from $175.00 to $210.00 and gave the company an "outperform" rating in a report on Friday, July 17th. Finally, Royal Bank Of Canada lifted their price target on Illumina from $170.00 to $230.00 and gave the company an "outperform" rating in a research note on Friday, July 31st. One equities research analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating, six have given a Hold rating and two have issued a Sell rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of "Hold" and a consensus price target of $188.40.
Read Our Latest Analysis on Illumina
Institutional Inflows and Outflows
A number of hedge funds have recently made changes to their positions in ILMN. Elyxium Wealth LLC acquired a new stake in shares of Illumina in the fourth quarter valued at approximately $25,000. TD Waterhouse Canada Inc. acquired a new position in shares of Illumina during the 4th quarter worth approximately $26,000. Laurel Wealth Advisors LLC purchased a new stake in Illumina in the 4th quarter valued at approximately $26,000. Fiduciary Financial Advisors purchased a new position in Illumina during the second quarter worth $26,000. Finally, Activest Wealth Management raised its holdings in shares of Illumina by 671.9% in the fourth quarter. Activest Wealth Management now owns 247 shares of the life sciences company's stock worth $32,000 after acquiring an additional 215 shares during the last quarter. Hedge funds and other institutional investors own 89.42% of the company's stock.
Illumina Company Profile
(
Get Free Report)
Illumina, Inc (NASDAQ: ILMN) is a global life sciences company that develops, manufactures and markets integrated systems for the analysis of genetic variation and function. Headquartered in San Diego, California and founded in 1998, Illumina offers a range of sequencing and array-based technologies used by academic researchers, clinical laboratories, pharmaceutical and biotechnology companies, consumer genomics firms and agricultural researchers to enable discovery, translational research and clinical applications.
The company's product portfolio includes next-generation sequencing (NGS) platforms and associated consumables, microarrays for genotyping and methylation analysis, library preparation kits and targeted assays.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
